Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration

Lykke M Ørnbjerg; Louise Linde; Stylianos Georgiadis; Simon H Rasmussen; Ulf Lindström; Johan Askling; Brigitte Michelsen; Daniela Di Giuseppe; Johan K Wallman; Karel Pavelka; Jakub Závada; Michael J Nissen; Gareth T Jones; Heikki Relas; Laura Pirilä; Matija Tomšič; Ziga Rotar; Arni Jon Geirsson; Bjorn Gudbjornsson; Eirik K Kristianslund; Irene van Sder Horst-Bruinsma; Anne Gitte Loft; Karin Laas; Florenzo Iannone; Addolorata Corrado; Adrian Ciurea; Maria J Santos; Helena Santos; Catalin Codreanu; Nurullah Akkoc; Ozgul S Gunduz; Bente Glintborg; Mikkel Østergaard; Merete Lund Hetland

doi:10.1016/j.semarthrit.2022.152081

Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration

Lykke M Ørnbjerg, Louise Linde^*, Stylianos Georgiadis, Simon H Rasmussen, Ulf Lindström, Johan Askling, Brigitte Michelsen, Daniela Di Giuseppe, Johan K Wallman, Karel Pavelka, Jakub Závada, Michael J Nissen, Gareth T Jones, Heikki Relas, Laura Pirilä, Matija Tomšič, Ziga Rotar, Arni Jon Geirsson, Bjorn Gudbjornsson, Eirik K KristianslundIrene van Sder Horst-Bruinsma, Anne Gitte Loft, Karin Laas, Florenzo Iannone, Addolorata Corrado, Adrian Ciurea, Maria J Santos, Helena Santos, Catalin Codreanu, Nurullah Akkoc, Ozgul S Gunduz, Bente Glintborg, Mikkel Østergaard, Merete Lund Hetland

^*Corresponding author for this work

Department for Rheumatology and Spine Diseases

Abstract

OBJECTIVES: In patients with axial spondyloarthritis (axSpA) initiating their first tumor necrosis factor alpha-inhibitor (TNFi), we aimed to identify common baseline predictors of Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP) inactive disease (primary objective) and clinically important improvement (CII) at 6 months, and drug retention at 12-months across 15 European registries.

METHODS: Baseline demographic and clinical characteristics were collected. Outcomes were investigated per registry and in pooled data using logistic regression analyses on multiply imputed data.

RESULTS: The consistency of baseline predictors in individual registries justified pooling the data. In the pooled dataset (n = 21,196), the 6-month rates for ASDAS inactive disease and ASDAS CII were 26% and 51%, and the 12-month drug retention rate 65% in patients with available data (n = 9,845, n = 6,948 and n = 21,196, respectively). Nine common baseline predictors of ASDAS inactive disease, ASDAS CII and 12-month drug retention were identified, and the odds ratios (95%-confidence interval) for ASDAS inactive disease were: age, per year: 0.97 (0.97-0.98), men vs. women: 1.88 (1.60-2.22), current vs. non-smoking: 0.76 (0.63-0.91), HLA-B27 positive vs. negative: 1.51 (1.20-1.91), TNF start year 2015-2018 vs. 2009-2014: 1.24 (1.06-1.45), CRP>10 vs. ≤10 mg/l: 1.49 (1.25-1.77), one unit increase in health assessment questionnaire (HAQ): 0.77 (0.58-1.03), one-millimeter (mm) increase in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) fatigue and spinal pain: 0.99 (0.99-1.00) and 0.99 (0.99-1.99), respectively CONCLUSION: Common baseline predictors of treatment response and adherence to TNFi could be identified across data from 15 European registries, indicating that they may be universal across different axSpA populations.

Original language	English
Article number	152081
Journal	Seminars in Arthritis and Rheumatism
Volume	56
Pages (from-to)	1-13
Number of pages	13
ISSN	0049-0172
DOIs	https://doi.org/10.1016/j.semarthrit.2022.152081
Publication status	Published - 2022

Access to Document

10.1016/j.semarthrit.2022.152081

Cite this

Ørnbjerg, L. M., Linde, L., Georgiadis, S., Rasmussen, S. H., Lindström, U., Askling, J., Michelsen, B., Giuseppe, D. D., Wallman, J. K., Pavelka, K., Závada, J., Nissen, M. J., Jones, G. T., Relas, H., Pirilä, L., Tomšič, M., Rotar, Z., Geirsson, A. J., Gudbjornsson, B., ... Hetland, M. L. (2022). Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration. Seminars in Arthritis and Rheumatism, 56, 1-13. Article 152081. https://doi.org/10.1016/j.semarthrit.2022.152081

Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration. / Ørnbjerg, Lykke M ; Linde, Louise ; Georgiadis, Stylianos et al.
In: Seminars in Arthritis and Rheumatism, Vol. 56, 152081, 2022, p. 1-13.

Research output: Contribution to journal › Journal article › Research › peer-review

Ørnbjerg, LM , Linde, L , Georgiadis, S, Rasmussen, SH, Lindström, U, Askling, J, Michelsen, B, Giuseppe, DD, Wallman, JK, Pavelka, K, Závada, J, Nissen, MJ, Jones, GT, Relas, H, Pirilä, L, Tomšič, M, Rotar, Z, Geirsson, AJ, Gudbjornsson, B, Kristianslund, EK, van Sder Horst-Bruinsma, I, Loft, AG, Laas, K, Iannone, F, Corrado, A, Ciurea, A, Santos, MJ, Santos, H, Codreanu, C, Akkoc, N, Gunduz, OS, Glintborg, B , Østergaard, M & Hetland, ML 2022, 'Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration', Seminars in Arthritis and Rheumatism, vol. 56, 152081, pp. 1-13. https://doi.org/10.1016/j.semarthrit.2022.152081

@article{d7b0366cbc79466997d1475ffc8baafb,

title = "Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration",

abstract = "OBJECTIVES: In patients with axial spondyloarthritis (axSpA) initiating their first tumor necrosis factor alpha-inhibitor (TNFi), we aimed to identify common baseline predictors of Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP) inactive disease (primary objective) and clinically important improvement (CII) at 6 months, and drug retention at 12-months across 15 European registries.METHODS: Baseline demographic and clinical characteristics were collected. Outcomes were investigated per registry and in pooled data using logistic regression analyses on multiply imputed data.RESULTS: The consistency of baseline predictors in individual registries justified pooling the data. In the pooled dataset (n = 21,196), the 6-month rates for ASDAS inactive disease and ASDAS CII were 26% and 51%, and the 12-month drug retention rate 65% in patients with available data (n = 9,845, n = 6,948 and n = 21,196, respectively). Nine common baseline predictors of ASDAS inactive disease, ASDAS CII and 12-month drug retention were identified, and the odds ratios (95%-confidence interval) for ASDAS inactive disease were: age, per year: 0.97 (0.97-0.98), men vs. women: 1.88 (1.60-2.22), current vs. non-smoking: 0.76 (0.63-0.91), HLA-B27 positive vs. negative: 1.51 (1.20-1.91), TNF start year 2015-2018 vs. 2009-2014: 1.24 (1.06-1.45), CRP>10 vs. ≤10 mg/l: 1.49 (1.25-1.77), one unit increase in health assessment questionnaire (HAQ): 0.77 (0.58-1.03), one-millimeter (mm) increase in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) fatigue and spinal pain: 0.99 (0.99-1.00) and 0.99 (0.99-1.99), respectively CONCLUSION: Common baseline predictors of treatment response and adherence to TNFi could be identified across data from 15 European registries, indicating that they may be universal across different axSpA populations.",

author = "{\O}rnbjerg, {Lykke M} and Louise Linde and Stylianos Georgiadis and Rasmussen, {Simon H} and Ulf Lindstr{\"o}m and Johan Askling and Brigitte Michelsen and Giuseppe, {Daniela Di} and Wallman, {Johan K} and Karel Pavelka and Jakub Z{\'a}vada and Nissen, {Michael J} and Jones, {Gareth T} and Heikki Relas and Laura Piril{\"a} and Matija Tom{\v s}i{\v c} and Ziga Rotar and Geirsson, {Arni Jon} and Bjorn Gudbjornsson and Kristianslund, {Eirik K} and {van Sder Horst-Bruinsma}, Irene and Loft, {Anne Gitte} and Karin Laas and Florenzo Iannone and Addolorata Corrado and Adrian Ciurea and Santos, {Maria J} and Helena Santos and Catalin Codreanu and Nurullah Akkoc and Gunduz, {Ozgul S} and Bente Glintborg and Mikkel {\O}stergaard and Hetland, {Merete Lund}",

note = "COPECARE Copyright {\textcopyright} 2022. Published by Elsevier Inc.",

year = "2022",

doi = "10.1016/j.semarthrit.2022.152081",

language = "English",

volume = "56",

pages = "1--13",

journal = "Seminars in Arthritis and Rheumatism",

issn = "0049-0172",

publisher = "W.B./Saunders Co",

}

TY - JOUR

T1 - Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors

T2 - Data from the EuroSpA collaboration

AU - Ørnbjerg, Lykke M

AU - Linde, Louise

AU - Georgiadis, Stylianos

AU - Rasmussen, Simon H

AU - Lindström, Ulf

AU - Askling, Johan

AU - Michelsen, Brigitte

AU - Giuseppe, Daniela Di

AU - Wallman, Johan K

AU - Pavelka, Karel

AU - Závada, Jakub

AU - Nissen, Michael J

AU - Jones, Gareth T

AU - Relas, Heikki

AU - Pirilä, Laura

AU - Tomšič, Matija

AU - Rotar, Ziga

AU - Geirsson, Arni Jon

AU - Gudbjornsson, Bjorn

AU - Kristianslund, Eirik K

AU - van Sder Horst-Bruinsma, Irene

AU - Loft, Anne Gitte

AU - Laas, Karin

AU - Iannone, Florenzo

AU - Corrado, Addolorata

AU - Ciurea, Adrian

AU - Santos, Maria J

AU - Santos, Helena

AU - Codreanu, Catalin

AU - Akkoc, Nurullah

AU - Gunduz, Ozgul S

AU - Glintborg, Bente

AU - Østergaard, Mikkel

AU - Hetland, Merete Lund

PY - 2022

Y1 - 2022

N2 - OBJECTIVES: In patients with axial spondyloarthritis (axSpA) initiating their first tumor necrosis factor alpha-inhibitor (TNFi), we aimed to identify common baseline predictors of Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP) inactive disease (primary objective) and clinically important improvement (CII) at 6 months, and drug retention at 12-months across 15 European registries.METHODS: Baseline demographic and clinical characteristics were collected. Outcomes were investigated per registry and in pooled data using logistic regression analyses on multiply imputed data.RESULTS: The consistency of baseline predictors in individual registries justified pooling the data. In the pooled dataset (n = 21,196), the 6-month rates for ASDAS inactive disease and ASDAS CII were 26% and 51%, and the 12-month drug retention rate 65% in patients with available data (n = 9,845, n = 6,948 and n = 21,196, respectively). Nine common baseline predictors of ASDAS inactive disease, ASDAS CII and 12-month drug retention were identified, and the odds ratios (95%-confidence interval) for ASDAS inactive disease were: age, per year: 0.97 (0.97-0.98), men vs. women: 1.88 (1.60-2.22), current vs. non-smoking: 0.76 (0.63-0.91), HLA-B27 positive vs. negative: 1.51 (1.20-1.91), TNF start year 2015-2018 vs. 2009-2014: 1.24 (1.06-1.45), CRP>10 vs. ≤10 mg/l: 1.49 (1.25-1.77), one unit increase in health assessment questionnaire (HAQ): 0.77 (0.58-1.03), one-millimeter (mm) increase in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) fatigue and spinal pain: 0.99 (0.99-1.00) and 0.99 (0.99-1.99), respectively CONCLUSION: Common baseline predictors of treatment response and adherence to TNFi could be identified across data from 15 European registries, indicating that they may be universal across different axSpA populations.

AB - OBJECTIVES: In patients with axial spondyloarthritis (axSpA) initiating their first tumor necrosis factor alpha-inhibitor (TNFi), we aimed to identify common baseline predictors of Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP) inactive disease (primary objective) and clinically important improvement (CII) at 6 months, and drug retention at 12-months across 15 European registries.METHODS: Baseline demographic and clinical characteristics were collected. Outcomes were investigated per registry and in pooled data using logistic regression analyses on multiply imputed data.RESULTS: The consistency of baseline predictors in individual registries justified pooling the data. In the pooled dataset (n = 21,196), the 6-month rates for ASDAS inactive disease and ASDAS CII were 26% and 51%, and the 12-month drug retention rate 65% in patients with available data (n = 9,845, n = 6,948 and n = 21,196, respectively). Nine common baseline predictors of ASDAS inactive disease, ASDAS CII and 12-month drug retention were identified, and the odds ratios (95%-confidence interval) for ASDAS inactive disease were: age, per year: 0.97 (0.97-0.98), men vs. women: 1.88 (1.60-2.22), current vs. non-smoking: 0.76 (0.63-0.91), HLA-B27 positive vs. negative: 1.51 (1.20-1.91), TNF start year 2015-2018 vs. 2009-2014: 1.24 (1.06-1.45), CRP>10 vs. ≤10 mg/l: 1.49 (1.25-1.77), one unit increase in health assessment questionnaire (HAQ): 0.77 (0.58-1.03), one-millimeter (mm) increase in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) fatigue and spinal pain: 0.99 (0.99-1.00) and 0.99 (0.99-1.99), respectively CONCLUSION: Common baseline predictors of treatment response and adherence to TNFi could be identified across data from 15 European registries, indicating that they may be universal across different axSpA populations.

UR - http://www.scopus.com/inward/record.url?scp=85135923596&partnerID=8YFLogxK

U2 - 10.1016/j.semarthrit.2022.152081

DO - 10.1016/j.semarthrit.2022.152081

M3 - Journal article

C2 - 35985172

SN - 0049-0172

VL - 56

SP - 1

EP - 13

JO - Seminars in Arthritis and Rheumatism

JF - Seminars in Arthritis and Rheumatism

M1 - 152081

ER -

Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration

Abstract

Access to Document

Other files and links

Fingerprint

Cite this